ALS/MND 2023: AMX0114 may enter clinical testing next year
Amylyx Pharmaceuticals is developing AMX0114, a new experimental treatment for amyotrophic lateral sclerosis (ALS) that’s designed to promote…
Articles by Marisa Wexler, MS
Changes in speech with ALS to be monitored in planned Phase 1b trial
A Phase 1b proof-of-concept clinical trial of the experimental oral therapy VRG50635 in people with amyotrophic lateral sclerosis (ALS)…
‘Molecular traps’ may help fend off nerve damage from gene mutations
Scientists have created new “molecular traps” that were able to improve survival in cell and fruit fly models of…
Implant may help patients to speak by decoding their thoughts better
A new advance in technology may pave the way for devices that could allow people with amyotrophic lateral sclerosis…
Gene activity altered in certain brain cells of people with C9-ALS
The genetic activity of certain brain cells, namely excitatory neurons and astrocytes, is altered in people with amyotrophic lateral…
Zydus launches Phase 2 trial of anti-inflammatory ZYIL1
Zydus Lifesciences has launched a Phase 2 clinical trial to evaluate the safety and effectiveness of its experimental anti-inflammatory…
TUDCA at higher daily dose seen to extend survival: ALS registry study
People with amyotrophic lateral sclerosis (ALS) who are treated daily with 1,000 mg or higher doses of tauroursodeoxycholic…
FDA advisory committee votes against NurOwn approval for ALS
In a nearly unanimous vote, an advisory committee to the U.S. Food and Drug Administration (FDA) said there’s not enough…
FDA questions NurOwn’s efficacy, quality ahead of today’s hearing
The U.S. Food and Drug Administration (FDA) has shared its major concerns with data available for NurOwn,…
New guidelines: All ALS patients should be offered genetic testing
Every person with amyotrophic lateral sclerosis (ALS) should be offered genetic testing to check for the most common…